The Roy J. Carver Center for Genomics Achieves Certified Service Provider Status for Roche NimbleGen Microarrays
Product News Aug 25, 2011
In May 2011, The University of Iowa, Roy J. Carver Center for Genomics (CCG), entered into an agreement with Roche NimbleGen to provide microarray services through the Roche NimbleGen Certified Service Provider (CSP) program.
In July 2011, after passing their rigorous certification test plan, CCG received official certification as a Roche NimbleGen CSP for two microarray applications: array Comparative Genomic Hybridization (CGH) and gene expression.
"As a certified service provider, The Roy J. Carver Center for Genomics (CCG) will provide a full range of services for Roche NimbleGen applications including the recently certified array CGH and gene expression. The CCG is the first academic center in the US to attain this status, which emphasizes our expertise and commitment to provide high quality data to our investigators”, said Dr. Harsha Doddapaneni, Director of CCG.
He further added, we have a dedicated climate controlled facility for processing all the critical array steps to ensure best quality results.
About this agreement, Dr. Bernd Fritzsch, DEO, Department of Biology of the CCG said, “The Roy J. Carver Center for Genomics is progressively exploring the opportunities inherent to the recent progress in genomic analysis. Becoming a certified service center for NimbleGen arrays is only the logical next step in this direction, guided by the leadership of Dr. H. Doddapaneni. Combined with the Developmental Studies Hybridoma Bank (DSHB), run expertly by Dr. David Soll, this is the second community outreach and service program provided by the Department of Biology to the Science Community. The collaboration with Roche NimbleGen is unique and signifies a strong liaison with a major force in genomics.”
“Roche NimbleGen is extremely excited to welcome the CCG as a Certified Service Provider for NimbleGen microarrays. This addition will provide more researchers with access to the innovative NimbleGen technologies, such as our ultra-high resolution 4.2M CGH arrays and high-throughput gene expression arrays. We look forward to this collaboration and the innovation and value it will provide to the research market” said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.